RT Journal Article
T1 Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain.
A1 Rodriguez-Lescure, A
A1 de la Peña, F A
A1 Aranda, E
A1 Calvo, A
A1 Felip, E
A1 Garrido, P
A1 Vera, R
K1 Access
K1 Barriers
K1 Biomarker
K1 Drug
K1 Equity
K1 Oncology
K1 Spain
AB The Spanish Society of Medical Oncology (SEOM) has carried out a study to analyse the conditions of access to oncology drugs in clinical practice in Spain. For the first time, the access of predictive biomarkers has also been analyzed. A questionnaire was sent to 146 hospitals in Spain to collect information on the process of approval of 11 oncology drugs of an unquestionable clinical benefit and five predictive biomarkers of mandatory determination for specific treatments. Results highlight the still existing differences in the access of oncology drugs, as well as the newly identified differences in the access to predictive biomarkers between Autonomous Communities (AACC) in Spain, as well as between different hospitals within the same Autonomous Community. Conclusions The SEOM considers it necessary to reduce the differences identified, increase homogeneity, and improve conditions of access to oncology drugs and biomarkers, and makes proposals to address these issues.
PB Elsevier
YR 2020
FD 2020-04-28
LK http://hdl.handle.net/10668/15732
UL http://hdl.handle.net/10668/15732
LA en
NO Rodríguez-Lescure A, de la Peña FA, Aranda E, Calvo A, Felip E, Garrido P, et al. Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain. Clin Transl Oncol. 2020 Dec;22(12):2253-2263
DS RISalud
RD Apr 18, 2025